Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
Ferreira APS, Seguro FS, Abdo ARN, Santos FM, Maciel FVR, Nardinelli L, Giorgi RR, Ruiz ARL, Ferreira MPS, Rego EM, Rocha V, Bendit I. Ferreira APS, et al. Among authors: nardinelli l. Ann Hematol. 2023 Jul;102(7):1761-1771. doi: 10.1007/s00277-023-05189-3. Epub 2023 Apr 13. Ann Hematol. 2023. PMID: 37052662 Free PMC article.
Evaluation of long-term outcomes, cytogenetic and molecular responses with imatinib mesylate in early and late chronic-phase chronic myeloid leukemia: a report from a single institute.
Bendit I, Sanabani SS, Conchon M, Serpa M, Novaes MM, Nardinelli L, Pereira TD, Tucunduva L, Ferreira Pde B, Dorlhiac-Llacer PE, Fischer Chamone Dde A. Bendit I, et al. Among authors: nardinelli l. Acta Haematol. 2012;128(4):223-32. doi: 10.1159/000339696. Epub 2012 Aug 22. Acta Haematol. 2012. PMID: 22922489 Clinical Trial.
Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance.
Rezende VM, Rivellis AJ, Gomes MM, Dörr FA, Novaes MM, Nardinelli L, Costa AL, Chamone DA, Bendit I. Rezende VM, et al. Among authors: nardinelli l. Rev Bras Hematol Hemoter. 2013;35(2):103-8. doi: 10.5581/1516-8484.20130030. Rev Bras Hematol Hemoter. 2013. PMID: 23741187 Free PMC article.
BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival.
Pagnano KB, Bendit I, Boquimpani C, De Souza CA, Miranda EC, Zalcberg I, Larripa I, Nardinelli L, Silveira RA, Fogliatto L, Spector N, Funke V, Pasquini R, Hungria V, Sérgio Chiattone C, Clementino N, Conchon M, Moiraghi EB, Lopez JL, Pavlovsky C, Pavlovsky MA, Cervera EE, Meillon LA, Simões B, Hamerschlak N, Bozzano AH, Mayta E, Cortes J, Bengió 5 On Behalf Of Latin American Leukemia Net Lalnet RM. Pagnano KB, et al. Among authors: nardinelli l. Cancer Invest. 2015 Aug 17. Online ahead of print. Cancer Invest. 2015. PMID: 26279306
BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Pagnano KB, Bendit I, Boquimpani C, De Souza CA, Miranda EC, Zalcberg I, Larripa I, Nardinelli L, Silveira RA, Fogliatto L, Spector N, Funke V, Pasquini R, Hungria V, Chiattone CS, Clementino N, Conchon M, Moiraghi EB, Lopez JL, Pavlovsky C, Pavlovsky MA, Cervera EE, Meillon LA, Simões B, Hamerschlak N, Bozzano AH, Mayta E, Cortes J, Bengió RM; Latin American Leukemia Net (LALNET). Pagnano KB, et al. Among authors: nardinelli l. Cancer Invest. 2015;33(9):451-8. doi: 10.3109/07357907.2015.1065499. Epub 2015 Aug 17. Cancer Invest. 2015. PMID: 26288116
18 results